Side-by-side · Research reference

5-Amino-1MQvsAdipotide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongAUTO-DRAFTED8/38 cited

BAnimal-StrongHUMAN-REVIEWED15/49 cited

5-Amino-1MQ

NNMT inhibitor · Methylation / SAM modulation

100–200 mgDaily dose (oral)Neelakantan 2018

AnimalEvidence levelNeelakantan 2018

HoursHalf-life (est)

Oral · Once daily fasted

Adipotide

Pro-apoptotic Vascular-Targeting Peptide · Preclinical Only

PreclinicalStatus

PHB1TargetHossen 2013

ApoptosisMechanismHossen 2013

IV · Systemic · Preclinical Protocols OnlyHossen 2013

01Mechanism of Action

Parameter

5-Amino-1MQ

Adipotide

Primary target

Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018

Prohibitin-1 (PHB1) on adipose vasculature endotheliumHossen 2013

Pathway

NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018

CKGGRAKDC domain binds PHB1 → Peptide internalisation → D(KLAKLAK)₂ mitochondrial membrane disruption

Downstream effect

Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018

Endothelial apoptosis → Adipose vascular collapse → Adipocyte involution → Weight loss

Feedback intact?

—

N/A — Direct apoptotic mechanism, non-hormonal

Origin

Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018

Synthetic bioconjugate: PHB1-targeting homing peptide + pro-apoptotic KLA sequence

Antibody development

—

02Dosage Protocols

Parameter

5-Amino-1MQ

Adipotide

Standard dose

100–200 mg / day oralNeelakantan 2018

Anecdotal community range; murine doses scaled.

—

Frequency

Once daily, fasted

Not specified in available data

Lower / starter dose

50 mg / day

—

Evidence basis

Animal-strong; no human RCT dataNeelakantan 2018

Preclinical animal models only

Duration

8–12 weeks per cycle

—

Form

Oral capsule

—

Timing

Morning fasted preferred

—

Half-life

Hours (estimated; no human PK published)

—

Animal dose (mouse)

—

Low dose (not specified in abstract)Hossen 2013

Systemic injection in diet-induced obesity (DIO) models.Hossen 2013

Route

—

Intravenous (systemic injection)

Human data

—

None — no clinical trials reported

03Metabolic / Fat Loss Evidence

Parameter

5-Amino-1MQ

Adipotide

Primary fat target

—

White adipose tissue (all depots)

Mechanism

—

Vascular apoptosis → adipose blood supply collapse → adipocyte deathHossen 2013

Body weight reduction

—

Significant reduction in DIO miceHossen 2013

Absolute values not provided in abstract.

Leptin levels

—

Significant decrease

Parallel to adipose mass reduction.

Effect on adipocytes

—

Antiobesity effect on dysfunctional adipose cells (adipocytes + macrophages)Hossen 2013

Ectopic fat

—

Reduction in ectopic fat depositionHossen 2013

Marker of dysfunctional adipose tissue / metabolic syndrome.

Species tested

—

Obese rhesus monkeys, DIO mice

Human translation

—

Unknown — no clinical trials

04Side Effects & Safety

Parameter

5-Amino-1MQ

Adipotide

GI symptoms

Mild nausea (anecdotal)

—

Methylation disruption

Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)

—

Long-term safety

Unknown — no human trials

—

Cancer risk

Unclear — NNMT also studied in oncology contexts

—

Pregnancy / OB

Avoid

—

Drug interactions

Theoretical with niacin / B-vitamin supplements

—

Safety profile

—

Unknown — preclinical data only

Vascular selectivity

—

Targets adipose vasculature; off-target vascular effects unknown

Apoptotic mechanism risk

—

Pro-apoptotic payload may affect unintended tissues if selectivity incomplete

Kidney / liver toxicity

—

Not reported in available data

Immunogenicity

—

Not assessed in available data

Absolute Contraindications

5-Amino-1MQ

·Pregnancy / breastfeeding
·Active malignancy

Adipotide

·Human use — not approved, no clinical safety data

Relative Contraindications

5-Amino-1MQ

·Methylation-sensitive conditions (MTHFR mutation)
·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)

Adipotide

·Any condition requiring intact adipose-tissue vascularisation

05Administration Protocol

Parameter

5-Amino-1MQ

Adipotide

1. Form

Oral capsule. No injection.

Intravenous injection (systemic) in preclinical models. No human protocols exist.

2. Administration

Take with water, fasted preferred.

Bioconjugate peptide. May also be encapsulated in nanoparticles (prohibitin-targeted nanoparticle formulation, KLA-PTNP, showed superior efficacy vs. free bioconjugate in mice).Hossen 2013

3. Timing

Morning fasted.

Low-dose systemic injection (exact dosing not specified in available abstract). Frequency and duration not detailed.Hossen 2013

4. Storage

Room temp ≤25 °C, dry place.

Not specified — likely requires peptide-grade lyophilised storage and reconstitution.

5. Caveat

Monitor B-vitamin status with chronic use.

—